2025-09-06 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK), incorporating the provided data:

**Report on Merck & Co Inc (MRK)**

**0. Executive Summary**

Merck (MRK) is currently underperforming relative to the S&P 500 (VOO). Recent news indicates potential positive developments in their pipeline. Analyst consensus leans towards a "Buy" rating, with a target price significantly above the current trading price. However, some technical indicators raise caution, and historical data shows periods of significant underperformance.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** MRK
*   **Company Name:** Merck & Co Inc
*   **Description:** A global pharmaceutical company that develops and manufactures medicines and vaccines.
*   **MRK Cumulative Return:** -7.64%
*   **VOO Cumulative Return:** 101.31%
*   **Relative Divergence:**
    *   **Max:** 23.1
    *   **Min:** -111.9
    *   **Current:** -106.9
    *   **Relative Divergence (% of Range):** 3.7%

**Analysis:** MRK has significantly underperformed the S&P 500 over the period examined. The relative divergence of -106.9 indicates substantial underperformance, positioned near the lowest end of its historical range relative to the S&P 500. The 3.7% relative divergence suggests it is near the bottom of its historical underperformance.

**Alpha, Beta Analysis Table**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2015-2017  | 5.0%    | 58.2% | -24.0%  | -0.0  | 134.1  |
| 2016-2018  | 43.0%   | 66.4% | 25.0%   | -0.1  | 182.1  |
| 2017-2019  | 40.0%   | 66.4% | 11.0%   | 0.3   | 216.8  |
| 2018-2020  | 20.0%   | 66.4% | 0.0%    | 0.3   | 195.0  |
| 2019-2021  | -1.0%   | 65.6% | -50.0%  | 0.3   | 191.4  |
| 2020-2022  | 13.0%   | 69.5% | 11.0%   | 0.3   | 277.1  |
| 2021-2023  | 31.0%   | 69.5% | 13.0%   | 0.3   | 272.3  |
| 2022-2024  | -7.0%   | 69.5% | -33.0%  | 0.2   | 248.5  |
| 2023-2025  | -60.0%  | 71.5% | -113.0% | 0.5   | 211.6  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate fluctuates significantly. The recent period (2023-2025) shows a substantial negative CAGR.
*   **MDD:** Maximum Drawdown is consistently high, indicating significant volatility.
*   **Alpha:** Alpha is often negative, meaning the stock has underperformed its benchmark (likely the S&P 500) after accounting for risk. The most recent period shows a very large negative alpha.
*   **Beta:** Beta is generally low (close to zero), suggesting low correlation with the market.

**2. Recent Stock Price Movements**

*   **Current Price:** 84.71
*   **Previous Close:** 84.05
*   **Change:** 0.79 (Slight increase, may reflect recent news, see #4)
*   **5-day Moving Average:** 84.341
*   **20-day Moving Average:** 83.8623
*   **60-day Moving Average:** 82.0591

**Analysis:** The stock price is currently trading above its 5-day, 20-day, and 60-day moving averages, indicating a short-term upward trend. The positive change of 0.79 from the previous close further supports this observation.

**3. Market Risk Indicator & Other Indicators**

*   **MRI:** 0.3322 (Low Risk)
*   **RSI:** 52.37 (Neutral)
*   **PPO:** -0.1239 (Slightly Bearish)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **20-day Relative Divergence Change:** 1.2 (Positive - Short-term Increase)
*   **Expected Return:** -340.9% (Significant Underperformance vs S&P 500 over a long-term investment horizon)

**Analysis:**

*   The Market Risk Indicator (MRI) suggests low market risk.
*   The Relative Strength Index (RSI) is near the neutral level, indicating neither overbought nor oversold conditions.
*   The Positive Price Oscillator (PPO) is slightly negative, which may indicate a bearish signal.
*   The change in relative divergence indicates a short-term increase in performance relative to the S&P 500, but still negative overall
*   The Hybrid Signal is recommending a 80% Buy, while signalling caution.
*   The extremely negative expected return is a significant red flag, suggesting very poor long-term performance relative to the S&P 500 if current trends continue.

**4. Recent News & Significant Events**

*   **Weight Loss Drugs (WHO):** Potential long-term market implications.
*   **US Bond Market Activity:** General market context.
*   **Cholesterol Drug Trial Results:** Positive news specific to Merck, likely driving the small price increase.
*   **Lyophilized Injectable Drugs Market:** Broader market trend relevant to Merck's business.
*   **NSCLC Trials & Eli Lilly's Drug:** Competitive landscape in lung cancer treatment.

**Analysis:** The news is a mixed bag. The positive news regarding the cholesterol drug trial is a potential catalyst. The competitive landscape in NSCLC should be watched.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (~1.96 on scale of 1-5)
*   **Opinions:** 24
*   **Target Price:**
    *   **Average:** 102.33
    *   **High:** 141.00
    *   **Low:** 82.00
*   **Recent Rating Changes:** Not Provided

**Analysis:** Analyst consensus is bullish, with an average target price significantly above the current price. This suggests analysts believe the stock is undervalued.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2025-08-05 | 2.15 | 16.11 B$ |

**Analysis:** Earnings per share (EPS) have fluctuated, showing inconsistent performance.  Revenue has also varied, but has generally been strong.

**6. Financial Information**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.81B   | 77.50%        |
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-06-30 | $48.99B   | 9.04%    |
| 2025-03-31 | $48.34B   | 10.51%   |
| 2024-12-31 | $46.31B   | 8.08%    |
| 2024-09-30 | $44.50B   | 7.09%    |
| 2024-06-30 | $43.58B   | 12.52%   |

**Analysis:**

*   **Revenue:** Relatively stable revenue stream.
*   **Profit Margin:** Consistently high profit margins, suggesting strong pricing power or cost management.
*   **Equity:** Increasing equity over the periods shown.
*   **ROE:** Return on Equity has fluctuated, but generally indicates good profitability relative to equity.

**7. Comprehensive Analysis**

Merck (MRK) presents a mixed picture.  Here's a summary of key takeaways:

*   **Underperformance:** Significant and persistent underperformance compared to the S&P 500 (VOO). The Expected Return of -340.9% should be a huge warning sign.
*   **Technicals:** Recent price movement is slightly positive. The MRI shows low risk, but the PPO is slightly negative.
*   **News:** Recent news is cautiously positive, with specific developments in cholesterol drug trials that might boost stock price.
*   **Analyst Sentiment:** Overwhelmingly positive, with high target prices.
*   **Financials:** Strong revenue, high profit margins, and growing equity.
*   **Earnings:** EPS is unstable, with varied revenue.

**Conclusion:**

While analysts are bullish and recent news is potentially positive, the historical underperformance relative to the S&P 500, large negative alpha, and poor expected return are causes for concern. The positive analyst sentiment and potential catalysts from the pipeline need to be weighed against these risks. A careful evaluation of the company's future prospects and competitive landscape is necessary before making an investment decision. A significant amount of caution should be considered before investing in MRK.
